HOME >> BIOLOGY >> NEWS
Metal-based medicine could treat diseases in the body

Washington, DC Designer molecules that combine metals such as copper with natural organic materials could one day attack viruses in the body and treat a wide range of diseases.

That's the finding of chemists at Ohio State University, who have successfully tested such molecules against portions of HIV and Hepatitis C virus RNA in the laboratory. They've also created molecules that act like ACE, or angiotensin-converting enzyme, inhibitors drugs that are used to lower blood pressure.

At the American Chemical Society national meeting in Washington, DC, project leader James Cowan described how the same patent-pending technology could one day produce novel anti-tumor agents.

Drugs based on these molecules could produce fewer side effects compared to some of today's treatments, and they could also combat drug resistance, said Cowan, professor of chemistry at Ohio State.

Pharmaceutical companies tend to make drugs from the same limited set of ingredients, drawing upon only about a half-dozen of the more than 100 known chemical elements, Cowan explained. At the same time, drug-resistant bacteria and viruses are emerging.

"Faced with a problem like that, you can't ignore 95 percent of the periodic table," he said. "We have to start broadening the landscape of drug design."

His new molecules, called metal coordination complexes, mimic the activity of natural enzymes that break apart DNA, RNA, and proteins in the body.

Cowan and his colleagues have tailor-made different complexes to break apart portions of RNA that enable HIV and Hepatitis C viruses to function, as well as the ACE enzyme that constricts blood vessels in the body. In test tubes and in cell cultures of E. coli, the complexes targeted these particular RNA structures and enzymes and destroyed them.

The complexes work in one of two ways. Some use a process called redox chemistry to steal electrons from the bonds holding the target molecule together.
'"/>

Contact: James Cowan
Cowan.2@osu.edu
614-292-2703
Ohio State University
30-Aug-2005


Page: 1 2 3

Related biology news :

1. Computer graphics spills from milk to medicine
2. New survey documents the headaches of computerized medicine
3. Discoverer of Sly Syndrome finds way of delivering medicine to fight rare genetic disorder
4. Nanotechnology, medicine and bioethics
5. Fly and worm models to teach researchers about human biology and medicine
6. Egyptians, not Greeks were true fathers of medicine
7. Stanford scientists make major breakthrough in regenerative medicine
8. Will nanotechnology revolutionize medicine?
9. Little lifesavers -- Nanoparticles improve delivery of medicines and diagnostics
10. Bronfman gift to Mount Sinai catalyzes genomics-based medicine
11. Advances in personalized medicine on agenda for 54th Society of Nucelar Medicine Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Metal based medicine could treat diseases the body

(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: